AML Awareness Day: Evolving Treatment Paradigms and Future Directions With Tristan E. Knight, MD

Understanding AML: A Disease of Complexity

AML is characterized by the accumulation of undifferentiated or poorly differentiated myeloid blasts in the blood and bone marrow. It is primarily a disease of older adults, with a median age of diagnosis at 68, but pediatric AML accounts for about 20% of pediatric acute leukemias.

The molecular heterogeneity of AML underpins its diverse clinical presentations and outcomes. Risk stratification, guided by genetic mutations and cytogenetic abnormalities, plays a critical role in determining treatment strategies. For example, favorable-risk mutations, such as NPM1 without FLT3-ITD, are associated with better outcomes, while adverse-risk mutations, such as TP53 or complex karyotypes, present significant therapeutic challenges.

Advances in Treatment: Targeted Therapies and Beyond

The treatment landscape for AML has evolved significantly over the past decade, with the introduction of targeted therapies and novel combinations. For younger, medically fit adults, the traditional backbone of treatment remains the 7+3 regimen (cytarabine and an anthracycline). However, newer agents, such as CPX-351, have shown promise, particularly in therapy-related AML. Dr. Knight notes, “The combination of hypomethylating agents like azacitidine or decitabine with venetoclax has become a new standard for older or less fit patients, offering improved response and survival rates.”

Targeted therapies, such as FLT3 inhibitors (midostaurin and gilteritinib) and IDH1/IDH2 inhibitors (ivosidenib and enasidenib), have transformed the treatment paradigm by addressing specific genetic mutations. These agents are increasingly being incorporated into frontline and salvage regimens, as well as post-transplant maintenance strategies. “The approval of targeted agents has dramatically improved outcomes for patients with specific mutations, but challenges like drug resistance and relapse remain,” Dr. Knight explains.

Pediatric AML: Unique Challenges and Opportunities

Pediatric AML differs biologically from adult AML, with fewer somatic mutations but more frequent chromosomal rearrangements. Children generally tolerate intensive chemotherapy better than adults, leading to higher cure rates of approximately 65%. Dr. Knight highlights, “In pediatric AML, long-term toxicity is a major concern, as we aim to balance curative treatment with minimizing late effects.”

Emerging therapies, including FLT3 inhibitors and immunotherapies, are being incorporated into pediatric clinical trials led by the Children’s Oncology Group. These efforts aim to refine treatment approaches and improve outcomes for high-risk pediatric patients.

The Role of Transplant and Immunotherapy

Allogeneic hematopoietic stem cell transplantation remains a cornerstone of curative therapy for high-risk AML. Advances in donor selection, such as haploidentical transplants, and post-transplant maintenance strategies are expanding access to this potentially life-saving treatment. However, post-transplant relapse remains a significant challenge. “It’s critical to plan for transplant early in the treatment course to optimize outcomes,” Dr. Knight advises.

Immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, is an area of active research in AML. Unlike other hematologic malignancies, AML lacks a clear antigenic target, complicating the development of effective immunotherapies. Dr. Knight remarks, “Despite these challenges, the potential of CAR T cells and bispecific antibodies in AML is promising, particularly as part of transplant conditioning regimens.”

Key Takeaways for Clinicians

1. Personalized Treatment: AML management is increasingly guided by genetic and molecular profiling, enabling more precise and effective therapies
2. Targeted Therapies: The integration of FLT3, IDH1/IDH2 inhibitors, and venetoclax into treatment regimens has improved outcomes, particularly for older and high-risk patients
3. Pediatric Considerations: Tailored approaches are essential for pediatric AML, with a focus on balancing efficacy and long-term toxicity
4. Transplantation: Early planning and post-transplant maintenance strategies are critical for achieving durable remissions
5. Immunotherapy: While still in its infancy for AML, immunotherapy holds great potential for future treatment paradigms

Dr. Knight concludes, “Our goal is not just to achieve remission but to provide durable, curative strategies with acceptable toxicity across diverse patient populations.” Continued research, clinical trials, and awareness efforts are essential to advancing care for AML patients and improving outcomes.

About Dr. Knight

Tristan E. Knight, MD, practices at Kapiolani Medical Center for Women and Children in Honolulu, Hawaii, where he specializes in pediatric hematology, oncology, and bone marrow transplant. He completed his Pediatric Residency at the University of Hawaii, a Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Michigan, and a Bone Marrow Transplant (BMT)/Cellular Therapy Fellowship at the Hospital for Sick Children (SickKids). Before returning to Hawaii, he practiced at Seattle Children’s Hospital / Fred Hutch Cancer Center for a number of years. His clinical areas of interest are allogeneic/autologous BMT and cellular/immune effector cell therapy, particularly in the treatment of children with ALL, AML, and neuroblastoma. He has published extensively on novel therapeutic approaches in these conditions, including the use of CAR T-cell therapy in children.